Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Depreciation and Depletion (2020 - 2022)

Historic Depreciation and Depletion for Protagonist Therapeutics (PTGX) over the last 3 years, with Q4 2022 value amounting to $254000.0.

  • Protagonist Therapeutics' Depreciation and Depletion rose 808.51% to $254000.0 in Q4 2022 from the same period last year, while for Dec 2022 it was $1.0 million, marking a year-over-year increase of 2693.73%. This contributed to the annual value of $894000.0 for FY2024, which is 849.54% down from last year.
  • According to the latest figures from Q4 2022, Protagonist Therapeutics' Depreciation and Depletion is $254000.0, which was up 808.51% from $270000.0 recorded in Q3 2022.
  • Protagonist Therapeutics' Depreciation and Depletion's 5-year high stood at $270000.0 during Q3 2022, with a 5-year trough of $180000.0 in Q1 2021.
  • For the 3-year period, Protagonist Therapeutics' Depreciation and Depletion averaged around $225888.9, with its median value being $235000.0 (2021).
  • Data for Protagonist Therapeutics' Depreciation and Depletion shows a peak YoY increase of 4000.0% (in 2022) and a maximum YoY decrease of 808.51% (in 2022) over the last 5 years.
  • Quarter analysis of 3 years shows Protagonist Therapeutics' Depreciation and Depletion stood at $188000.0 in 2020, then increased by 25.0% to $235000.0 in 2021, then increased by 8.09% to $254000.0 in 2022.
  • Its last three reported values are $254000.0 in Q4 2022, $270000.0 for Q3 2022, and $259000.0 during Q2 2022.